MMPP
Based on 1 Customer Validation
MMPP is an orally active inhibitor of STAT3 and VEGFR2, as well as an activator of PPARγ. MMPP blocks the VEGFR2/AKT/ERK/NF-κB signaling pathway to inhibit angiogenesis. MMPP inhibits ferroptosis and inflammation, and alleviates sepsis-induced myocardial injury. MMPP induces G1-phase cell cycle arrest and apoptosis, and inhibits the growth of non-small cell lung cancer (NSCLC) and solid tumors. MMPP promotes adipogenesis and glucose uptake. MMPP can be used in research related to NSCLC, type 2 diabetes and myocardial injury.
For research use only. We do not sell to patients.
- Purity : 98.06%
- CAS No.: 1895957-18-2
- Formula: C17H18O3
- Molecular Weight:270.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All VEGFR Isoforms
More
Biological Activity
Description
|
STAT3 |
VEGFR2 |
PPARγ |
In Vitro
MMPP inhibits the viability of NCI-H460 non-small cell lung cancer cells, with an IC50 value of 12.3 μg/mL[1].
MMPP (5-20 μg/mL; 24 h) inhibits the viability of various cancer cell lines, including the NCI-H460 non-small cell lung cancer cell line, in a concentration-dependent manner (IC50 = 11.99 μg/mL), but exerts no effect on the viability of non-cancerous LL-24 lung epithelial cells[1].
MMPP (5-15 μg/mL; 24 h) induces apoptosis and G1-phase cell cycle arrest in NCI-H460 and A549 non-small cell lung cancer cells in a concentration-dependent manner[1].
MMPP (10 μg/mL; 24 h) significantly inhibits VEGFA-induced migration of human umbilical vein endothelial cells (HUVECs) in scratch wound healing assays[2].
MMPP (10 μg/mL) significantly inhibits VEGFA-induced invasion of HUVECs in Transwell assays[2].
MMPP (10 μg/mL; 16 h) significantly inhibits VEGFA-induced angiogenesis in HUVECs[2].
MMPP (10 μg/mL; 1.5 h) inhibits the VEGFR2/AKT/ERK signaling pathway in HUVECs by reducing the phosphorylation levels of VEGFR2, AKT and ERK[2].
MMPP (10 μg/mL; 2 h) inhibits VEGFA-induced nuclear translocation of NF-κB p65 in HUVECs[2].
MMPP (10 μg/mL; 25 h) significantly downregulates the mRNA expression of VEGFA, VEGFR2, MMP2 and MMP9 in HUVECs[2].
MMPP (15 μg/mL; 24 h) upregulates the transcriptional activity of PPARγ in HEK 293T cells, and synergistically enhances this activity with Rosiglitazone (HY-17386)[3].
MMPP (7.5-15 μg/mL; 2-8 days) dose-dependently promotes lipid accumulation in differentiated 3T3-L1 MBX adipocytes[3].
MMPP (7.5-15 μg/mL; 2-8 days) increases glucose uptake in mature 3T3-L1 MBX adipocytes[3].
MMPP (7.5-15 μg/mL; 2-8 days) enhances the expression of adipogenesis-related genes and reduces Il6 mRNA levels in mature 3T3-L1 MBX adipocytes[3].
MMPP (7.5-15 μg/mL; 2-8 days) enhances the expression of adipogenesis-related proteins in fully differentiated 3T3-L1 MBX adipocytes[3].
MMPP (7.5-15 μg/mL; 2-8 days) upregulates the expression of C/ebpb mRNA in early-stage (day 2) 3T3-L1 MBX adipocytes[3].
MMPP (7.5-15 μg/mL; 2-8 days) upregulates the expression of C/EBPβ protein in early-stage (day 2) 3T3-L1 MBX adipocytes[3].
MMPP (7.5-15 μg/mL; 1 h) enhances the phosphorylation levels of AKT, GSK3 and AMPKα in 3T3-L1 MBX cells co-treated with MDI for 1 h[3].
MMPP (5-100 mg/L; 10 min) potently scavenges ABTS•+ in a cell-free system, and achieves nearly complete inhibition at a concentration of 100 mg/L[4].
MMPP (40-200 mg/L) scavenges •OH in a cell-free system, with a scavenging rate of 48.14% at 200 mg/L[4].
MMPP (100-1000 mg/L) scavenges O2•- in a cell-free system, with a scavenging rate of 61.24% at 1000 mg/L[4].
MMPP (100-500 mg/L; 1 h) chelates Fe2+ in a cell-free system, with a chelating efficiency of up to 51.0% at the concentration of 500 mg/L[4].
MMPP (100 μg/mL; 12.5 h) restores the viability of H9c2 cells treated with LPS (HY-D1056) after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) reduces LDH release in LPS-treated neonatal rat ventricular myocytes after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) reduces the Ptgs2 mRNA expression level in neonatal rat ventricular myocytes treated with LPS after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) reduces the PTGS2 protein expression level in LPS-treated neonatal rat ventricular myocytes after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) inhibits LPS-induced release of cytochrome c (Cyt c) from mitochondria to cytoplasm in neonatal rat ventricular myocytes after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) reduces the MDA level in neonatal rat ventricular myocytes treated with LPS after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) restores SOD levels in LPS-treated neonatal rat ventricular myocytes after 12 hours of incubation[4].
MMPP (100 μg/mL; 12.5 h) reduces intracellular ROS accumulation in lipopolysaccharide-treated neonatal rat ventricular myocytes after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) reduces lipid ROS accumulation in neonatal rat ventricular myocytes treated with LPS after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) maintains the mitochondrial membrane potential of lipopolysaccharide-treated neonatal rat ventricular cardiomyocytes after 12 h of incubation[4].
MMPP (100 μg/mL; 12.5 h) maintains mitochondrial function in LPS-treated neonatal rat ventricular cardiomyocytes after 12 h of incubation[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:multiple cancer cell lines (colon: HCT116, SW480; prostate: PC3, LNCaP; ovary: PA-1, SK-OV-3; liver: Hep-G2, Huh-7; breast: MCF-7; skin: SK-MEL-28; lung: A549, NCI-H460) and non-cancerous LL-24 lung epithelial cells
-
Concentration:5, 10, 15 and 20 μg/mL
-
Incubation Time:24 h
-
Result:Significantly reduced viability of all tested cancer cell lines at 10 μg/mL.
Reduced viability of NCI-H460 cells in a concentration-dependent manner with an IC50 of 11.99 μg/mL.
Showed no toxicity to non-cancerous LL-24 lung epithelial cells at tested concentrations.
-
Cell Line:NCI-H460 and A549 NSCLC cells
-
Concentration:5, 10 and 15 μg/mL
-
Incubation Time:24 h
-
Result:Induced apoptosis in NCI-H460 and A549 cells in a concentration-dependent manner, with the apoptotic index increasing from near 0% in vehicle controls to ~60% at 15 μg/mL MMPP in NCI-H460 cells.
-
Cell Line:NCI-H460 and A549 NSCLC cells
-
Concentration:5, 10 and 15 μg/mL
-
Incubation Time:24 h
-
Result:Increased expression of pro-apoptotic proteins Bax, cleaved caspase-3, and cleaved caspase-8, and decreased expression of anti-apoptotic protein Bcl-2 in a concentration-dependent manner.
Increased expression of cell cycle inhibitor p21, and decreased expression of CDK6 and cyclin D1 in a concentration-dependent manner.
-
Cell Line:NCI-H460 and A549 NSCLC cells transfected with wild-type or T456A mutant STAT3
-
Concentration:10 μg/mL
-
Incubation Time:24 h
-
Result:Inhibited viability and induced G1-phase cell cycle arrest in cells transfected with wild-type STAT3, but these inhibitory effects were attenuated in cells transfected with STAT3-T456A mutant.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:10 μg/mL
-
Incubation Time:24 h
-
Result:Resulted in a wider scratched area compared to VEGFA-stimulated controls.
Significantly inhibited VEGFA-induced HUVEC migration.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:10 μg/mL
-
Incubation Time:1 h pre-incubation, followed by 30 min VEGFA stimulation
-
Result:Reduced the phosphorylation levels of VEGFR2, AKT, and ERK.
Left total protein levels unchanged.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:10 μg/mL
-
Incubation Time:1 h pre-incubation, followed by 24 h VEGFA stimulation
-
Result:Significantly suppressed the mRNA expressions of VEGFA, VEGFR2, MMP2, and MMP9.
-
Cell Line:fully differentiated 3T3-L1 MBX adipocytes
-
Concentration:7.5 and 15 μg/mL
-
Incubation Time:added on day 2, day 4, and day 6 of differentiation, with incubation through day 8
-
Result:Increased the protein expression levels of adipogenic transcription factors (PPARγ, C/EBPα) and markers (GLUT4, FAS, ACC) in a dose-dependent manner, compared to the MDI-only control group.
-
Cell Line:early-stage (day 2) 3T3-L1 MBX adipocytes
-
Concentration:7.5 and 15 μg/mL
-
Incubation Time:48 h (from day 0 to day 2 of differentiation)
-
Result:Increased the mRNA expression level of C/ebpb in a dose-dependent manner, with significantly higher levels at 15 μg/mL compared to the MDI-only control group.
-
Cell Line:early-stage (day 2) 3T3-L1 MBX adipocytes
-
Concentration:7.5 and 15 μg/mL
-
Incubation Time:48 h (from day 0 to day 2 of differentiation)
-
Result:Increased the protein expression level of C/EBPβ in a dose-dependent manner, with significantly higher levels at both tested concentrations compared to the MDI-only control group.
-
Cell Line:3T3-L1 MBX cells
-
Concentration:7.5 and 15 μg/mL
-
Incubation Time:1 h (co-treatment with MDI)
-
Result:Enhanced the phosphorylation levels of AKT, GSK3, and AMPKα in a dose-dependent manner, with significantly higher phosphorylation levels at both tested concentrations compared to the MDI-only control group.
-
Cell Line:H9c2 cells
-
Concentration:100 μg/mL
-
Incubation Time:12 h (after 30 min LPS pre-treatment)
-
Result:Restored H9c2 cell viability from ~60% (LPS-treated group) to ~90% relative to the control group.
-
Cell Line:neonatal rat ventricular cardiomyocytes
-
Concentration:100 μg/mL
-
Incubation Time:12 h (after 30 min LPS pre-treatment)
-
Result:Reduced Ptgs2 mRNA levels from ~3.5-fold change (LPS-treated group) to ~2-fold change relative to the control group.
-
Cell Line:neonatal rat ventricular cardiomyocytes
-
Concentration:100 μg/mL
-
Incubation Time:12 h (after 30 min LPS pre-treatment)
-
Result:Reduced PTGS2 protein levels from ~1.8-fold change (LPS-treated group) to ~1-fold change relative to the control group.
Restored cytoplasmic Cyt c levels from ~0.7 relative units (vs. mitochondrial VDAC1) to ~1 relative unit, and reduced levels from ~1 relative unit (vs. cytoplasmic GAPDH) to ~0.3 relative units.
In Vivo
MMPP (5 mg/kg; p.o.; three times per week; for 1 month) significantly inhibits tumor growth in patient-derived NSCLC xenograft models in immunodeficient mice by suppressing STAT3 activity, with no observed toxicity[1].
MMPP (5 mg/kg; i.p.; twice weekly; for 3 consecutive weeks) inhibits tumor growth and STAT3 activity in BALB/c nude mice bearing A549 non-small cell lung cancer xenografts[1].
MMPP (5 mg/kg; i.p.; twice weekly; for 3 consecutive weeks) inhibits tumor growth and STAT3 activity in BALB/c nude mice bearing HCT116 colon cancer xenografts[1].
MMPP (5 mg/kg; i.p.; twice a week; for 3 consecutive weeks) inhibits tumor growth and STAT3 activity in BALB/c nude mice bearing PA-1 ovarian cancer xenografts[1].
MMPP (1 mg; intravenous injection; single dose) inhibits ferroptosis via iron chelation, alleviates oxidative stress, reduces the production of pro-inflammatory cytokines, attenuates sepsis-induced myocardial injury, improves the 14-day survival rate of C57BL/6J mice, and restores key cardiac function parameters including ejection fraction and fractional shortening[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:2.5 mg/kg; 5 mg/kg
-
Administration:i.p.; twice a week; 3 weeks; p.o.; three times a week; 3 weeks
-
Result:Significantly reduced tumor volume and weight compared to vehicle controls at 2.5 mg/kg i.p..
Produced a greater, dose-dependent reduction in tumor volume and weight at 5 mg/kg i.p..
Significantly inhibited tumor growth at 5 mg/kg p.o..
Reduced expression of p-STAT3, PCNA, and cyclin D1, and increased active caspase-3 in treated tumors via immunohistochemical staining.
Decreased levels of Cdk4, Cdk6, cyclin D1, and Bcl-2, and increased levels of Bax, cleaved caspase-3, and cleaved caspase-8 in tumor tissues via western blot analysis.
Inhibited STAT3 DNA-binding activity and nuclear translocation of p-STAT3 in tumor tissues.
-
Animal Model:Immunodeficient mice[1]
-
Dosage:5 mg/kg
-
Administration:p.o.; three times a week; 1 month
-
Result:Significantly reduced final tumor volume and weight compared to vehicle controls.
Suppressed p-STAT3 expression in tumor tissues via immunohistochemical analysis.
Inhibited STAT3 DNA-binding activity and reduced nuclear translocation of p-STAT3 via EMSA and western blot analysis.
Showed no signs of body weight loss or liver toxicity in treated animals.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; twice a week; 3 weeks
-
Result:Effectively suppressed tumor growth and STAT3 activity in A549 xenograft tumors.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; twice a week; 3 weeks
-
Result:Effectively suppressed tumor growth and STAT3 activity in HCT116 xenograft tumors.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; twice a week; 3 weeks
-
Result:Effectively suppressed tumor growth and STAT3 activity in PA-1 xenograft tumors.
Demonstrated superior antitumor activity to cisplatin (5 mg/kg) and similar antitumor activity to docetaxel (5 mg/kg).
-
Animal Model:C57BL/6J (adult male, 7-8 weeks old, 18 g-20 g, intravenous injection of 10 mg/kg LPS to induce sepsis)[4]
-
Dosage:1 mg
-
Administration:i.v.; single dose
-
Result:Increased 14-day survival rate significantly compared to the LPS-only group.
Reduced serum CK-MB from ~10000 pg/mL to ~5000 pg/mL.
Reduced serum LDH from ~45 U/mL to ~25 U/mL.
Restored left ventricular ejection fraction (EF%) from ~40% to ~60%.
Restored left ventricular fractional shortening (FS%) from ~20% to ~30%.
Reduced cardiac Ptgs2 mRNA fold change from ~7 to ~2.
Reduced cardiac PTGS2 protein fold change from ~2 to ~1.
Reduced cardiac MDA levels from ~650 nmol/g protein to ~400 nmol/g protein.
Increased cardiac SOD levels from ~25 U/g protein to ~35 U/g protein.
Reduced cardiac iron levels from ~8 μmol/g protein to ~6 μmol/g protein.
Reduced serum IL-1β from ~30 pg/mL to ~10 pg/mL.
Reduced serum TNF-α from ~80 pg/mL to ~30 pg/mL.
Reduced serum IL-6 from ~35000 pg/mL to ~20000 pg/mL.
Alleviated sepsis-induced cardiac inflammation, hemorrhage, and structural disorders.
Chemical Information
-
CAS No. 1895957-18-2
-
Appearance Solid
-
Molecular Weight 270.32
-
Formula C17H18O3
-
Color Off-white to light brown
-
SMILES
OC1=CC=C(C=C1OC)/C=C/CC2=CC=C(C=C2)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (369.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.25 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.25 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
3T3-L1 preadipocyte-to-adipocyte differentiation
3T3-L1 preadipocytes are induced to differentiate after growth arrest using adipogenic media containing insulin, dexamethasone, and IBMX; differentiation is assessed by lipid-droplet accumulation, triglyceride increase, Oil Red O staining, and adipocyte-marker induction such as PPARγ and C/EBPα.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Lipid Droplets: Oil Red O/Sudan Dye Lipid Staining
Lipid droplets are intracellular organelles with a neutral-lipid core that stores triacylglycerols and sterol esters, and Oil Red O or Sudan dyes detect these hydrophobic lipid deposits by partitioning into retained lipids in fresh or frozen specimens. Oil Red O stains neutral triglycerides and lipids in frozen tissue sections or air-dried cytologic preparations, while Sudan Black B has also been used as a histochemical fat stain for lipid-rich tissue structures.
Purity & Documentation
-
Data Sheet (304 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Son DJ, et al. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity Direct Binding to the STAT3 DNA-Binding Domain. Theranostics. 2017;7(18):4632-4642. [Content Brief]
[2]. Kim NY, et al. MMPP is a novel VEGFR2 inhibitor that suppresses angiogenesis via VEGFR2/AKT/ERK/NF-κB pathway. BMB reports. 2024 May;57(5):244-249. [Content Brief]
[3].
Kim NY, et al. MMPP promotes adipogenesis and glucose uptake via binding to the PPARγ ligand binding domain in 3T3-L1 MBX cells. Front Pharmacol. 2022 Oct 21;13:994584.
[Content Brief]
[4]. Liu C, et al. Melanin nanoparticles alleviate sepsis-induced myocardial injury by suppressing ferroptosis and inflammation. Bioactive materials. 2023 Jun;24:313-321. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6993 mL | 18.4966 mL | 36.9932 mL | 92.4830 mL |
| 5 mM | 0.7399 mL | 3.6993 mL | 7.3986 mL | 18.4966 mL | |
| 10 mM | 0.3699 mL | 1.8497 mL | 3.6993 mL | 9.2483 mL | |
| 15 mM | 0.2466 mL | 1.2331 mL | 2.4662 mL | 6.1655 mL | |
| 20 mM | 0.1850 mL | 0.9248 mL | 1.8497 mL | 4.6241 mL | |
| 25 mM | 0.1480 mL | 0.7399 mL | 1.4797 mL | 3.6993 mL | |
| 30 mM | 0.1233 mL | 0.6166 mL | 1.2331 mL | 3.0828 mL | |
| 40 mM | 0.0925 mL | 0.4624 mL | 0.9248 mL | 2.3121 mL | |
| 50 mM | 0.0740 mL | 0.3699 mL | 0.7399 mL | 1.8497 mL | |
| 60 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5414 mL | |
| 80 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 1.1560 mL | |
| 100 mM | 0.0370 mL | 0.1850 mL | 0.3699 mL | 0.9248 mL |